These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25715767)

  • 1. Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors.
    Oh DY; Kim TM; Han SW; Shin DY; Lee YG; Lee KW; Kim JH; Kim TY; Jang IJ; Lee JS; Bang YJ
    Cancer Res Treat; 2016 Jan; 48(1):28-36. PubMed ID: 25715767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer.
    Jeong H; Hong YS; Kim JE; Lim HS; Ahn JB; Shin SJ; Park YS; Kim ST; Han SW; Kim TY; Kim TW
    Invest New Drugs; 2021 Oct; 39(5):1335-1347. PubMed ID: 33829355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors.
    Oh DY; Lee SH; Han SW; Kim MJ; Kim TM; Kim TY; Heo DS; Yuasa M; Yanagihara Y; Bang YJ
    Cancer Res Treat; 2015 Oct; 47(4):607-15. PubMed ID: 25715763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
    Bendell JC; Patel MR; Infante JR; Kurkjian CD; Jones SF; Pant S; Burris HA; Moreno O; Esquibel V; Levin W; Moore KN
    Cancer; 2015 Apr; 121(7):1056-63. PubMed ID: 25411085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of the vascular-disrupting agent CKD-516 (NOV120401) in patients with refractory solid tumors.
    Kim HK; Kang JW; Park YW; Kim JY; Kim M; Kim SJ; Kim SM; Ho Ryu K; Yoon S; Kim Y; Cho JY; Lee KS; Yun T; Kim K; Kwak MH; Kim TS; Chung J; Park JW
    Pharmacol Res Perspect; 2020 Apr; 8(2):e00568. PubMed ID: 32162844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of pazopanib plus TH-302 in advanced solid tumors.
    Riedel RF; Meadows KL; Lee PH; Morse MA; Uronis HE; Blobe GC; George DJ; Crawford J; Niedzwiecki D; Rushing CN; Arrowood CC; Hurwitz HI
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):611-619. PubMed ID: 28238078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.
    Beg MS; Brenner AJ; Sachdev J; Borad M; Kang YK; Stoudemire J; Smith S; Bader AG; Kim S; Hong DS
    Invest New Drugs; 2017 Apr; 35(2):180-188. PubMed ID: 27917453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors.
    Shiah HS; Chiang NJ; Lin CC; Yen CJ; Tsai HJ; Wu SY; Su WC; Chang KY; Wang CC; Chang JY; Chen LT
    Oncologist; 2021 Apr; 26(4):e567-e579. PubMed ID: 33245172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
    Cunningham C; Appleman LJ; Kirvan-Visovatti M; Ryan DP; Regan E; Vukelja S; Bonate PL; Ruvuna F; Fram RJ; Jekunen A; Weitman S; Hammond LA; Eder JP
    Clin Cancer Res; 2005 Nov; 11(21):7825-33. PubMed ID: 16278405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.
    Elez E; Gomez-Roca C; Soto Matos-Pita A; Argiles G; Valentin T; Coronado C; Iglesias J; Macarulla T; Betrian S; Fudio S; Zaragoza K; Tabernero J; Delord JP
    Invest New Drugs; 2019 Aug; 37(4):674-683. PubMed ID: 30411218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
    Bendell JC; Rodon J; Burris HA; de Jonge M; Verweij J; Birle D; Demanse D; De Buck SS; Ru QC; Peters M; Goldbrunner M; Baselga J
    J Clin Oncol; 2012 Jan; 30(3):282-90. PubMed ID: 22162589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors.
    Ricart AD; Ashton EA; Cooney MM; Sarantopoulos J; Brell JM; Feldman MA; Ruby KE; Matsuda K; Munsey MS; Medina G; Zambito A; Tolcher AW; Remick SC
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):959-70. PubMed ID: 21305290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
    Strickler JH; Weekes CD; Nemunaitis J; Ramanathan RK; Heist RS; Morgensztern D; Angevin E; Bauer TM; Yue H; Motwani M; Parikh A; Reilly EB; Afar D; Naumovski L; Kelly K
    J Clin Oncol; 2018 Nov; 36(33):3298-3306. PubMed ID: 30285518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.
    Doi T; Shitara K; Kojima T; Yoshino T; Dontabhaktuni A; Rebscher H; Tang S; Cosaert J; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1253-62. PubMed ID: 27139036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors.
    Jones RL; Kim ES; Nava-Parada P; Alam S; Johnson FM; Stephens AW; Simantov R; Poondru S; Gedrich R; Lippman SM; Kaye SB; Carden CP
    Clin Cancer Res; 2015 Feb; 21(4):693-700. PubMed ID: 25208878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors.
    Infante JR; Mendelson DS; Burris HA; Bendell JC; Tolcher AW; Gordon MS; Gillenwater HH; Arastu-Kapur S; Wong HL; Papadopoulos KP
    Invest New Drugs; 2016 Apr; 34(2):216-24. PubMed ID: 26924128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumors.
    Campone M; Isambert N; Bourbouloux E; Maury S; Monin-Baroille P; Berille J; Fumoleau P
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):689-95. PubMed ID: 17031647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.
    Demetri GD; Lo Russo P; MacPherson IR; Wang D; Morgan JA; Brunton VG; Paliwal P; Agrawal S; Voi M; Evans TR
    Clin Cancer Res; 2009 Oct; 15(19):6232-40. PubMed ID: 19789325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.